About the Anthrax Vaccine

There is one anthrax vaccine licensed for use in humans in the United States by the Food and Drug Administration. Learn about the type, composition, immunogenicity, and effectiveness of this vaccine, as well as view the package insert, below.

Composition of the Anthrax Vaccine

Each 0.5 milliliter (mL) dose of anthrax vaccine adsorbed or BioThrax® (Emergent BioSolutions) is made from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis. Each dose includes the 83kDa protective antigen protein and 1.2 milligrams per milliliter (mg/mL) aluminum. Each dose also includes the following preservatives: 25 micrograms per milliliter (µg/mL) benzethonium chloride and 100 µg/mL formaldehyde. The vaccine contains no dead or live bacteria.

Immunogenicity and Vaccine Effectiveness

The anthrax vaccine is effective at protecting most people from anthrax, including inhalation anthrax. The effectiveness of the anthrax vaccine is around 93% for people completing the primary series and maintaining the booster vaccinations.

Package Inserts

Consult the following package inserts for proper storage and handing details, shelf life, and reconstitution instructions:

• BioThrax®